2025-06-09-Jefferies-街头传闻-上周重点_ADUS_AHCO_DNTL_RDNT及政策_8页_248kb

Summary of Word on the Street – Last Week's Focus: ADUS, AHCO, DNTL, RDNT & Policy

Core Content Overview

This report highlights the performance of several healthcare service companies and discusses recent developments in the sector, including mergers, acquisitions, and policy changes. The overall market performance is compared with the performance of specific companies and sub-sectors, with a focus on the impact of regulatory and macroeconomic factors on the industry.

Market Performance

• S&P 500: +1.5% for the week, +7.0% for the month, +2.0% YTD, +12.1% 1Y.
• Healthcare Service Companies: +0.3% for the week, +3.9% for the month, +15.3% YTD, +9.6% 1Y.
• Sub-Sector Performance:
  • Healthcare Staffing & Other Svcs: -1.3% (1W), +3.1% (1M), +2.0% (YTD), +30.3% (1Y)
  • Medical Equipment & Med Device Svcs: -0.9% (1W), +0.6% (1M), -6.5% (YTD), -13.8% (1Y)
  • Post-Acute Care: +1.9% (1W), +9.0% (1M), +19.5% (YTD), +28.4% (1Y)
  • Pharma Distribution/Services: -0.2% (1W), +1.7% (1M), +31.4% (YTD), +16.2% (1Y)
  • Behavioral Health: +0.4% (1W), -4.5% (1M), -42.6% (YTD), -68.1% (1Y)
  • Hospitals: +1.0% (1W), +18.6% (1M), +31.5% (YTD), +14.0% (1Y)
  • Outpatient Specialty Services: +0.2% (1W), +9.0% (1M), +14.6% (YTD), +4.2% (1Y)
  • Value-Based Care: +0.4% (1W), -23.6% (1M), +4.1% (YTD), -24.8% (1Y)

Company Highlights

ADUS (Addus HomeCare Corporation)

• Performance: +2.0% (1W), +4.2% (1M), -9.7% (YTD), -1.4% (1Y)
• Key Points:
  • Management hosted an NDR, viewing Medicaid spending cuts as minimal risk.
  • Work requirements may expand the part-time labor pool.
  • Benefiting from a favorable rate environment, including a ~10% rate increase in Texas effective Sep-25.
  • Expected to support 3-5% PCS revenue growth through 2026.
  • Operational improvements and tech initiatives are expected to lift order fill rates.
  • Focused on disciplined M&A, targeting strategic tuck-in deals in high-margin states.

AHCO (AdaptHealth Corp.)

• Performance: -0.9% (1W), +0.6% (1M), -6.5% (YTD), -13.8% (1Y)
• Key Points:
  • OMI & Rotech terminated a proposed deal due to regulatory hurdles.
  • Market reacted positively, with OMI shares rising +14%.
  • The acquisition would have increased exposure to the CPAP/Respiratory segment, which faces structural headwinds due to GLP-1 adoption.

DNTL (Dentalcorp Holdings Ltd.)

• Performance: -3.8% (1W), +0.2% (1M), +3.0% (YTD), +14.9% (1Y)
• Key Points:
  • Management reaffirmed 3-5% SS revenue growth and +DD% EBITDA growth.
  • Projected 25-35 bps annual margin improvement.
  • Strategy to double the business over five years, driven by 10% top-line growth and $35 MM of acquired EBITDA.
  • Margins expected to expand by 200 bps to reach the high-end of 18%.
  • Strong free cash flow profile (60-65% EBITDA conversion).
  • Focused on Canadian market consolidation, with U.S. expansion under evaluation.

RDNT (RadNet, Inc.)

• Performance: +2.0% (1W), +10.0% (1M), -16.0% (YTD), -3.9% (1Y)
• Key Points:
  • Acquiring See-Mode Technologies, an AI company with FDA-approved tech for thyroid ultrasounds.
  • Expected to reduce scan times by 30%, boosting revenue and EBITDA.
  • While some investors prefer clinic acquisitions, management maintains valuation discipline.
  • AI deals like See-Mode and ICAD are seen as strategically valuable.
  • Expect the bulk of cash to be deployed toward clinic acquisitions in the next 24 months.

Policy Updates

• Medicaid Cuts: Previously untouchable, now facing potential scaling back by GOP senators.
• Medicare Scrutiny: Potential adjustments to Medicare could be under review for "fraud, waste, and abuse".
• CBO Scoring: A tax bill combined with the expiration of eAPTCs is projected to save $863BB over the next decade and result in 16MM individuals losing insurance coverage.

Investment Recommendations

• BUY: ADUS, ATGE, ACHC, BKY, BTSG, BKD, CVS, CAH, ASTH, EHC, EHAB, HCA, LFST, MCK, EYE, OPCH, MD, PRVA, RDNT, THC, USPH, UNH
• HOLD: AHCO, AMN, CCRN, WBA, CYH, MODV, AGL

Key Risks and Disclosures

• The report may include conflicts of interest due to Jefferies' business relationships with covered companies.
• Investment ratings are not guarantees of future performance.
• Currency risk is noted for non-US denominated securities.
• Jefferies may have a conflict of interest, and investors are advised to consider the report as one of many factors in their decision-making.

Valuation Methodology

• Ratings are based on market capitalization, growth/value, volatility, and expected total return over 12 months.
• Price targets are derived from multiple methodologies, including DCF, EBITDA, P/E, and EV/EBITDA.

Analyst Certification

• All analysts certify that the views expressed in the report reflect their personal views.
• Analyst compensation is based on firm performance, including investment banking income.
• Research may be updated, but regulatory constraints may limit such updates.

Summary of Key Themes

• M&A Activity: Companies like ADUS and RDNT are pursuing strategic acquisitions, with ADUS focusing on high-margin states and RDNT evaluating AI and clinic acquisitions.
• Regulatory Impact: Medicaid and Medicare policy changes are being closely watched, with potential implications for the sector.
• Performance Variability: Sub-sectors show varied performance, with Post-Acute Care and Pharma Distribution/Services outperforming others.
• Investor Sentiment: Market reactions to deal terminations and M&A activity indicate mixed sentiment, with relief for some and caution for others.
• Valuation Discipline: Management is maintaining disciplined valuations, particularly for RDNT, while also focusing on high-impact acquisitions.